Moss, 6 May 2026

Following a comprehensive review of performance data and market dynamics,
Gentian Diagnostics ASA ("Gentian" or the "Company") has decided to discontinue
the development program for its heart failure biomarker NT-proBNP. This decision
reflects disciplined portfolio prioritisation and enables reallocation of
resources toward higher-return opportunities within the company's expanding
product pipeline. 

Despite extensive re optimization efforts that improved assay imprecision and
overall analytical chemistry performance, available data indicate that the assay
is not expected to reliably meet the clinical decision cut-off for exclusion of
non-acute heart failure. Achieving these requirements would likely necessitate a
substantially extended development program with high technical risk. In
addition, market assessments indicate limited commercial demand for an acute
only NT proBNP assay as a standalone product in an increasingly competitive and
saturated market.

After evaluating a range of strategic alternatives and considering the overall
risk profile, development timelines, and opportunity cost, the Company has
decided to terminate the NT proBNP assay development project. The project has
been fully written off, and an impairment charge of NOK 30.2 million has been
recognised in the Q1'26 accounts.  The impairment does not impact the company's
cash position and should be seen in the context of active portfolio management
and capital discipline.

The development work has generated valuable technical data and insights that
will be retained to support future biomarker and assay platform development
initiatives. Commenting on the decision, Matti Heinonen, CEO of Gentian
Diagnostics ASA, said:
"While this outcome is disappointing, it is a disciplined decision that allows
us to reallocate resources toward accelerating execution of Gentian's expanding
product pipeline. This includes a combination of proprietary assay programs and
partnered development projects with leading global IVD companies. We continue to
strengthen the alignment between our R&D and Business Development activities,
prioritising projects with clear market needs, defined routes to
commercialisation, and strong partner interest."

Gentian will continue to provide updates on pipeline development and strategic
priorities through its regular financial reporting.

IR contact: 
Njaal Kind, CEO 
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro
diagnostic reagents. Our mission is to improve diagnostic efficiency to support
better treatment decisions. Gentian's expertise and focus lie in immunoassays,
specifically within infections, inflammation, kidney disease, and heart failure.
By converting existing, clinically relevant biomarkers to the most efficient
high throughput analysers, the company contributes to cost savings and helps
protect lives. Gentian Diagnostics is headquartered in Moss, Norway, and serves
the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, the USA, and China. For more information,
please visit www.gentian.com.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17, Section 5-12 the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business
Controller and IR at Gentian Diagnostics ASA on the date and time provided.